 Brian Cole
Concepts (796)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cartilage, Articular | 119 | 2023 | 587 | 28.910 |
Why?
| | Knee Joint | 145 | 2023 | 812 | 24.920 |
Why?
| | Menisci, Tibial | 69 | 2023 | 175 | 22.120 |
Why?
| | Knee Injuries | 74 | 2022 | 226 | 18.750 |
Why?
| | Arthroscopy | 140 | 2023 | 811 | 14.880 |
Why?
| | Osteoarthritis, Knee | 55 | 2022 | 384 | 14.760 |
Why?
| | Cartilage Diseases | 39 | 2023 | 83 | 13.810 |
Why?
| | Platelet-Rich Plasma | 42 | 2021 | 73 | 13.320 |
Why?
| | Shoulder Joint | 95 | 2023 | 571 | 11.610 |
Why?
| | Anterior Cruciate Ligament Reconstruction | 60 | 2023 | 235 | 11.200 |
Why?
| | Bone Transplantation | 40 | 2023 | 232 | 10.950 |
Why?
| | Rotator Cuff | 54 | 2023 | 262 | 10.770 |
Why?
| | Osteotomy | 28 | 2022 | 163 | 9.780 |
Why?
| | Allografts | 52 | 2023 | 184 | 9.760 |
Why?
| | Orthopedic Procedures | 45 | 2021 | 320 | 8.780 |
Why?
| | Humans | 533 | 2023 | 32988 | 8.740 |
Why?
| | Transplantation, Homologous | 68 | 2023 | 297 | 8.430 |
Why?
| | Cartilage | 28 | 2021 | 168 | 7.500 |
Why?
| | Chondrocytes | 44 | 2022 | 215 | 7.460 |
Why?
| | Tibia | 33 | 2022 | 260 | 6.860 |
Why?
| | Joint Instability | 50 | 2023 | 389 | 6.760 |
Why?
| | Treatment Outcome | 144 | 2023 | 4036 | 6.150 |
Why?
| | Adult | 209 | 2023 | 9848 | 6.090 |
Why?
| | Biological Products | 10 | 2023 | 44 | 6.050 |
Why?
| | Femur | 36 | 2022 | 403 | 5.830 |
Why?
| | Reoperation | 58 | 2022 | 970 | 5.510 |
Why?
| | Tendon Injuries | 26 | 2022 | 194 | 5.500 |
Why?
| | Male | 250 | 2023 | 17726 | 5.420 |
Why?
| | Female | 230 | 2023 | 18423 | 4.990 |
Why?
| | Young Adult | 93 | 2023 | 2287 | 4.960 |
Why?
| | Shoulder | 34 | 2022 | 155 | 4.870 |
Why?
| | Return to Work | 12 | 2021 | 54 | 4.860 |
Why?
| | Osteoarthritis | 26 | 2023 | 399 | 4.800 |
Why?
| | Follow-Up Studies | 72 | 2023 | 2053 | 4.700 |
Why?
| | Middle Aged | 180 | 2022 | 11219 | 4.640 |
Why?
| | Adolescent | 88 | 2023 | 2687 | 4.500 |
Why?
| | Arthroplasty, Subchondral | 12 | 2018 | 27 | 4.440 |
Why?
| | Athletic Injuries | 26 | 2020 | 182 | 4.350 |
Why?
| | Anterior Cruciate Ligament | 41 | 2023 | 271 | 4.320 |
Why?
| | Retrospective Studies | 91 | 2023 | 3835 | 4.250 |
Why?
| | Wound Healing | 23 | 2021 | 178 | 4.240 |
Why?
| | Arthroplasty | 28 | 2022 | 134 | 4.200 |
Why?
| | Tenodesis | 22 | 2023 | 152 | 4.110 |
Why?
| | Suture Techniques | 23 | 2022 | 149 | 4.030 |
Why?
| | Orthopedics | 13 | 2023 | 133 | 4.010 |
Why?
| | Transplantation, Autologous | 46 | 2023 | 221 | 3.630 |
Why?
| | Osteochondritis Dissecans | 9 | 2019 | 27 | 3.620 |
Why?
| | Patellofemoral Joint | 14 | 2023 | 52 | 3.550 |
Why?
| | Injections, Intra-Articular | 27 | 2022 | 90 | 3.440 |
Why?
| | Hyaluronic Acid | 17 | 2021 | 113 | 3.350 |
Why?
| | Pain | 26 | 2023 | 407 | 3.320 |
Why?
| | Patient Satisfaction | 22 | 2021 | 325 | 3.200 |
Why?
| | Shoulder Dislocation | 15 | 2021 | 87 | 3.160 |
Why?
| | Magnetic Resonance Imaging | 35 | 2023 | 1315 | 3.140 |
Why?
| | Suture Anchors | 15 | 2023 | 71 | 3.090 |
Why?
| | Range of Motion, Articular | 55 | 2023 | 710 | 2.970 |
Why?
| | Fractures, Stress | 5 | 2021 | 21 | 2.940 |
Why?
| | Arthroplasty, Replacement, Knee | 13 | 2023 | 705 | 2.830 |
Why?
| | Biomechanical Phenomena | 51 | 2022 | 726 | 2.770 |
Why?
| | Sports Medicine | 7 | 2022 | 43 | 2.660 |
Why?
| | Pain, Postoperative | 12 | 2022 | 321 | 2.460 |
Why?
| | Recovery of Function | 23 | 2020 | 312 | 2.330 |
Why?
| | Pain Measurement | 27 | 2022 | 479 | 2.310 |
Why?
| | Joint Diseases | 9 | 2020 | 113 | 2.280 |
Why?
| | Tendons | 20 | 2023 | 219 | 2.250 |
Why?
| | Postoperative Complications | 24 | 2021 | 1117 | 2.240 |
Why?
| | Cadaver | 44 | 2022 | 366 | 2.060 |
Why?
| | Humeral Head | 7 | 2021 | 26 | 2.040 |
Why?
| | Anesthetics, Local | 5 | 2019 | 88 | 2.030 |
Why?
| | Chondrogenesis | 7 | 2020 | 30 | 1.930 |
Why?
| | Ligaments, Articular | 14 | 2022 | 106 | 1.910 |
Why?
| | Prospective Studies | 36 | 2023 | 2002 | 1.850 |
Why?
| | Graft Survival | 11 | 2020 | 110 | 1.800 |
Why?
| | Debridement | 17 | 2018 | 101 | 1.800 |
Why?
| | Aged | 78 | 2021 | 10542 | 1.780 |
Why?
| | Cohort Studies | 36 | 2023 | 2077 | 1.750 |
Why?
| | Radiography | 24 | 2020 | 717 | 1.700 |
Why?
| | Postoperative Period | 22 | 2022 | 298 | 1.680 |
Why?
| | Scapula | 11 | 2020 | 80 | 1.600 |
Why?
| | Tendinopathy | 10 | 2021 | 64 | 1.600 |
Why?
| | Bone Marrow | 9 | 2023 | 75 | 1.580 |
Why?
| | Sutures | 5 | 2021 | 46 | 1.560 |
Why?
| | Growth Plate | 2 | 2020 | 28 | 1.530 |
Why?
| | Bone Screws | 8 | 2023 | 185 | 1.520 |
Why?
| | Quality of Life | 20 | 2022 | 747 | 1.510 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 368 | 1.470 |
Why?
| | Physical Examination | 15 | 2019 | 117 | 1.420 |
Why?
| | Psychometrics | 4 | 2021 | 292 | 1.420 |
Why?
| | Stem Cell Transplantation | 4 | 2020 | 52 | 1.420 |
Why?
| | Tissue Engineering | 6 | 2012 | 50 | 1.380 |
Why?
| | Absorbable Implants | 6 | 2014 | 25 | 1.380 |
Why?
| | Activities of Daily Living | 12 | 2022 | 515 | 1.350 |
Why?
| | Athletes | 11 | 2022 | 83 | 1.350 |
Why?
| | Treatment Failure | 15 | 2020 | 186 | 1.330 |
Why?
| | Research Design | 5 | 2020 | 244 | 1.320 |
Why?
| | Animals | 41 | 2022 | 5371 | 1.320 |
Why?
| | Adrenal Cortex Hormones | 6 | 2021 | 113 | 1.270 |
Why?
| | Intra-Articular Fractures | 5 | 2020 | 16 | 1.260 |
Why?
| | Bone Malalignment | 3 | 2016 | 20 | 1.220 |
Why?
| | Tomography, X-Ray Computed | 18 | 2020 | 899 | 1.220 |
Why?
| | Muscle, Skeletal | 16 | 2022 | 391 | 1.210 |
Why?
| | Upper Extremity | 9 | 2021 | 47 | 1.210 |
Why?
| | United States | 30 | 2021 | 2632 | 1.210 |
Why?
| | Time Factors | 25 | 2021 | 1873 | 1.190 |
Why?
| | Autografts | 9 | 2023 | 32 | 1.190 |
Why?
| | Quality Improvement | 3 | 2019 | 173 | 1.170 |
Why?
| | Patient Selection | 10 | 2020 | 261 | 1.150 |
Why?
| | Tissue Transplantation | 6 | 2016 | 20 | 1.150 |
Why?
| | Viscosupplementation | 4 | 2020 | 8 | 1.120 |
Why?
| | Postoperative Care | 11 | 2020 | 140 | 1.110 |
Why?
| | Patella | 11 | 2022 | 82 | 1.110 |
Why?
| | Viscosupplements | 4 | 2020 | 13 | 1.110 |
Why?
| | Imaging, Three-Dimensional | 14 | 2020 | 235 | 1.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 233 | 1.090 |
Why?
| | Baseball | 9 | 2017 | 107 | 1.080 |
Why?
| | Hyaline Cartilage | 6 | 2020 | 15 | 1.060 |
Why?
| | Bupivacaine | 3 | 2012 | 56 | 1.050 |
Why?
| | Arthralgia | 11 | 2020 | 125 | 1.040 |
Why?
| | Bone and Bones | 5 | 2018 | 125 | 1.010 |
Why?
| | Surgeons | 3 | 2021 | 98 | 1.000 |
Why?
| | Preoperative Period | 6 | 2020 | 71 | 0.980 |
Why?
| | Reproducibility of Results | 13 | 2021 | 893 | 0.970 |
Why?
| | Recurrence | 16 | 2021 | 400 | 0.970 |
Why?
| | Musculoskeletal Diseases | 2 | 2023 | 42 | 0.960 |
Why?
| | X-Ray Microtomography | 4 | 2021 | 74 | 0.960 |
Why?
| | Fibrin Tissue Adhesive | 4 | 2022 | 9 | 0.950 |
Why?
| | Glenoid Cavity | 5 | 2015 | 34 | 0.950 |
Why?
| | Computer Simulation | 10 | 2022 | 248 | 0.940 |
Why?
| | Intercellular Signaling Peptides and Proteins | 4 | 2013 | 62 | 0.940 |
Why?
| | Hemiarthroplasty | 4 | 2022 | 31 | 0.930 |
Why?
| | Writing | 1 | 2023 | 23 | 0.920 |
Why?
| | Ossification, Heterotopic | 2 | 2022 | 42 | 0.910 |
Why?
| | Artificial Intelligence | 1 | 2023 | 26 | 0.910 |
Why?
| | Humerus | 9 | 2019 | 105 | 0.880 |
Why?
| | Elbow Joint | 7 | 2015 | 131 | 0.870 |
Why?
| | Acromion | 6 | 2018 | 27 | 0.870 |
Why?
| | Extracellular Matrix | 2 | 2021 | 91 | 0.870 |
Why?
| | Venous Thrombosis | 2 | 2017 | 55 | 0.860 |
Why?
| | Patellar Ligament | 8 | 2023 | 52 | 0.850 |
Why?
| | Arthritis | 5 | 2016 | 114 | 0.840 |
Why?
| | Arm | 9 | 2022 | 83 | 0.810 |
Why?
| | Incidence | 11 | 2019 | 840 | 0.790 |
Why?
| | Child | 13 | 2022 | 1634 | 0.780 |
Why?
| | Double-Blind Method | 7 | 2022 | 546 | 0.780 |
Why?
| | Amnion | 2 | 2020 | 5 | 0.770 |
Why?
| | Databases, Factual | 9 | 2019 | 393 | 0.770 |
Why?
| | Cell Separation | 1 | 2020 | 45 | 0.760 |
Why?
| | Anesthesia, Dental | 1 | 2019 | 1 | 0.760 |
Why?
| | Carticaine | 1 | 2019 | 1 | 0.760 |
Why?
| | Pulmonary Embolism | 2 | 2018 | 58 | 0.740 |
Why?
| | Stem Cells | 1 | 2020 | 54 | 0.740 |
Why?
| | Exercise Therapy | 4 | 2017 | 119 | 0.740 |
Why?
| | Genu Varum | 1 | 2019 | 3 | 0.740 |
Why?
| | Basketball | 3 | 2016 | 11 | 0.730 |
Why?
| | Rupture | 14 | 2021 | 117 | 0.730 |
Why?
| | Cumulative Trauma Disorders | 3 | 2017 | 16 | 0.720 |
Why?
| | Leukocytes | 3 | 2016 | 49 | 0.710 |
Why?
| | Muscle Strength | 5 | 2017 | 134 | 0.710 |
Why?
| | Catheter Ablation | 4 | 2008 | 88 | 0.700 |
Why?
| | Shoulder Pain | 5 | 2017 | 55 | 0.700 |
Why?
| | Risk Factors | 21 | 2020 | 2762 | 0.690 |
Why?
| | Nerve Block | 1 | 2019 | 63 | 0.690 |
Why?
| | Age Factors | 15 | 2021 | 932 | 0.670 |
Why?
| | Patellofemoral Pain Syndrome | 2 | 2017 | 3 | 0.670 |
Why?
| | Patient Outcome Assessment | 5 | 2018 | 49 | 0.670 |
Why?
| | Stifle | 1 | 2018 | 12 | 0.650 |
Why?
| | Football | 5 | 2018 | 38 | 0.650 |
Why?
| | Proteoglycans | 10 | 2022 | 412 | 0.640 |
Why?
| | Evidence-Based Medicine | 8 | 2020 | 235 | 0.640 |
Why?
| | Regeneration | 3 | 2011 | 30 | 0.620 |
Why?
| | Bone Morphogenetic Proteins | 4 | 2011 | 102 | 0.610 |
Why?
| | Patient Preference | 1 | 2017 | 38 | 0.610 |
Why?
| | Health Literacy | 1 | 2018 | 106 | 0.610 |
Why?
| | Soccer | 3 | 2018 | 20 | 0.610 |
Why?
| | Randomized Controlled Trials as Topic | 14 | 2022 | 377 | 0.600 |
Why?
| | Workers' Compensation | 6 | 2021 | 59 | 0.600 |
Why?
| | Physical Therapy Modalities | 6 | 2019 | 81 | 0.600 |
Why?
| | Synovial Fluid | 2 | 2017 | 137 | 0.600 |
Why?
| | Second-Look Surgery | 5 | 2020 | 13 | 0.590 |
Why?
| | Stress, Mechanical | 9 | 2020 | 190 | 0.590 |
Why?
| | Sodium Chloride | 1 | 2016 | 45 | 0.590 |
Why?
| | Soft Tissue Injuries | 2 | 2016 | 17 | 0.590 |
Why?
| | Bone-Patellar Tendon-Bone Grafting | 8 | 2023 | 44 | 0.580 |
Why?
| | Prognosis | 10 | 2019 | 1011 | 0.580 |
Why?
| | Lysholm Knee Score | 4 | 2021 | 6 | 0.570 |
Why?
| | Cytokines | 7 | 2018 | 372 | 0.560 |
Why?
| | Time-to-Treatment | 2 | 2015 | 37 | 0.560 |
Why?
| | Patient Education as Topic | 2 | 2017 | 193 | 0.560 |
Why?
| | Weight-Bearing | 9 | 2018 | 184 | 0.550 |
Why?
| | Prostheses and Implants | 5 | 2008 | 174 | 0.550 |
Why?
| | Tenotomy | 1 | 2015 | 16 | 0.550 |
Why?
| | Quadriceps Muscle | 4 | 2020 | 27 | 0.550 |
Why?
| | Tissue Donors | 3 | 2019 | 85 | 0.540 |
Why?
| | Tissue Adhesives | 2 | 2019 | 11 | 0.540 |
Why?
| | Lidocaine | 2 | 2019 | 41 | 0.530 |
Why?
| | Sterilization | 2 | 2014 | 10 | 0.530 |
Why?
| | Knee Prosthesis | 2 | 2016 | 248 | 0.530 |
Why?
| | Multivariate Analysis | 10 | 2021 | 386 | 0.530 |
Why?
| | Analgesics, Opioid | 4 | 2022 | 224 | 0.520 |
Why?
| | Ontario | 3 | 2020 | 18 | 0.510 |
Why?
| | Cell Survival | 10 | 2020 | 185 | 0.510 |
Why?
| | Serial Publications | 1 | 2014 | 1 | 0.510 |
Why?
| | Transforming Growth Factor beta | 3 | 2008 | 128 | 0.500 |
Why?
| | Collateral Ligaments | 2 | 2013 | 24 | 0.500 |
Why?
| | Osteochondritis | 2 | 2011 | 4 | 0.500 |
Why?
| | Cryopreservation | 2 | 2018 | 25 | 0.500 |
Why?
| | Cost-Benefit Analysis | 5 | 2022 | 159 | 0.490 |
Why?
| | Aged, 80 and over | 20 | 2018 | 5249 | 0.490 |
Why?
| | Anti-Infective Agents, Local | 1 | 2014 | 53 | 0.480 |
Why?
| | Chlorhexidine | 1 | 2014 | 61 | 0.480 |
Why?
| | Athletic Performance | 4 | 2020 | 22 | 0.480 |
Why?
| | Case-Control Studies | 9 | 2020 | 694 | 0.480 |
Why?
| | Gymnastics | 2 | 2010 | 5 | 0.470 |
Why?
| | Disease Models, Animal | 9 | 2021 | 844 | 0.460 |
Why?
| | Rabbits | 7 | 2015 | 336 | 0.460 |
Why?
| | Sex Factors | 6 | 2019 | 548 | 0.450 |
Why?
| | Drug Therapy, Combination | 2 | 2011 | 261 | 0.440 |
Why?
| | Random Allocation | 9 | 2019 | 162 | 0.440 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2011 | 62 | 0.430 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2022 | 113 | 0.400 |
Why?
| | Cells, Cultured | 5 | 2020 | 803 | 0.400 |
Why?
| | Clinical Competence | 3 | 2019 | 284 | 0.390 |
Why?
| | Therapeutic Irrigation | 5 | 2013 | 69 | 0.390 |
Why?
| | Anti-Inflammatory Agents | 3 | 2014 | 111 | 0.380 |
Why?
| | Algorithms | 6 | 2020 | 428 | 0.380 |
Why?
| | Ulna | 1 | 2010 | 29 | 0.380 |
Why?
| | Pilot Projects | 5 | 2019 | 466 | 0.380 |
Why?
| | Tissue and Organ Harvesting | 3 | 2005 | 23 | 0.380 |
Why?
| | Rotation | 12 | 2018 | 157 | 0.380 |
Why?
| | Fractures, Cartilage | 1 | 2010 | 4 | 0.380 |
Why?
| | Biocompatible Materials | 6 | 2016 | 122 | 0.380 |
Why?
| | Arthroplasty, Replacement | 5 | 2014 | 149 | 0.370 |
Why?
| | Tendon Transfer | 3 | 2015 | 23 | 0.370 |
Why?
| | Models, Animal | 6 | 2015 | 147 | 0.370 |
Why?
| | Cattle | 7 | 2019 | 260 | 0.370 |
Why?
| | Fibrocartilage | 2 | 2015 | 9 | 0.360 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2010 | 319 | 0.350 |
Why?
| | Methylprednisolone | 1 | 2009 | 22 | 0.350 |
Why?
| | Demography | 2 | 2019 | 82 | 0.350 |
Why?
| | Hemostasis, Surgical | 2 | 2006 | 19 | 0.340 |
Why?
| | Brachial Plexus | 1 | 2008 | 5 | 0.340 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 216 | 0.340 |
Why?
| | Child, Preschool | 3 | 2021 | 798 | 0.340 |
Why?
| | Decompression, Surgical | 2 | 2012 | 145 | 0.330 |
Why?
| | Lower Extremity Deformities, Congenital | 1 | 2008 | 2 | 0.330 |
Why?
| | Freezing | 1 | 2008 | 14 | 0.330 |
Why?
| | Rats | 5 | 2020 | 972 | 0.330 |
Why?
| | Wounds and Injuries | 4 | 2019 | 60 | 0.330 |
Why?
| | Patient Positioning | 2 | 2020 | 39 | 0.320 |
Why?
| | Conflict of Interest | 2 | 2019 | 19 | 0.320 |
Why?
| | Patient Care Planning | 2 | 2005 | 59 | 0.320 |
Why?
| | Graft Rejection | 5 | 2014 | 87 | 0.320 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2007 | 3 | 0.320 |
Why?
| | Physician Incentive Plans | 1 | 2007 | 3 | 0.310 |
Why?
| | Lower Extremity | 2 | 2018 | 43 | 0.310 |
Why?
| | Salaries and Fringe Benefits | 1 | 2007 | 12 | 0.310 |
Why?
| | Tissue Scaffolds | 3 | 2015 | 27 | 0.310 |
Why?
| | Patellar Dislocation | 2 | 2019 | 21 | 0.310 |
Why?
| | Electric Stimulation | 1 | 2007 | 89 | 0.310 |
Why?
| | Information Systems | 3 | 2021 | 19 | 0.300 |
Why?
| | Decision Making | 2 | 2011 | 239 | 0.300 |
Why?
| | Prosthesis Failure | 2 | 2014 | 581 | 0.300 |
Why?
| | Bone Resorption | 2 | 2019 | 106 | 0.290 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2006 | 26 | 0.290 |
Why?
| | Preoperative Care | 4 | 2020 | 148 | 0.290 |
Why?
| | Visual Analog Scale | 3 | 2020 | 49 | 0.290 |
Why?
| | Severity of Illness Index | 7 | 2020 | 1242 | 0.290 |
Why?
| | Models, Anatomic | 3 | 2013 | 68 | 0.290 |
Why?
| | Ankle Joint | 2 | 2019 | 41 | 0.280 |
Why?
| | Physicians | 3 | 2019 | 136 | 0.280 |
Why?
| | Foreign-Body Migration | 1 | 2006 | 25 | 0.280 |
Why?
| | Academic Medical Centers | 1 | 2007 | 162 | 0.280 |
Why?
| | Patient Readmission | 2 | 2018 | 134 | 0.280 |
Why?
| | Depression | 2 | 2021 | 533 | 0.280 |
Why?
| | Organ Preservation | 1 | 2005 | 9 | 0.280 |
Why?
| | Pain Management | 1 | 2007 | 145 | 0.280 |
Why?
| | Tennis Elbow | 2 | 2019 | 13 | 0.270 |
Why?
| | Bursa, Synovial | 1 | 2005 | 9 | 0.270 |
Why?
| | Electrocoagulation | 1 | 2005 | 17 | 0.270 |
Why?
| | Burns | 1 | 2005 | 26 | 0.270 |
Why?
| | Sensitivity and Specificity | 5 | 2014 | 592 | 0.270 |
Why?
| | Cell Transplantation | 3 | 2010 | 30 | 0.270 |
Why?
| | Connective Tissue | 3 | 2013 | 28 | 0.270 |
Why?
| | Materials Testing | 4 | 2017 | 143 | 0.260 |
Why?
| | Collagen Type III | 3 | 2015 | 14 | 0.260 |
Why?
| | Collagen Type I | 3 | 2015 | 18 | 0.260 |
Why?
| | Shoulder Impingement Syndrome | 3 | 2014 | 11 | 0.260 |
Why?
| | Posterior Cruciate Ligament | 3 | 2020 | 23 | 0.260 |
Why?
| | Equipment Design | 5 | 2017 | 207 | 0.250 |
Why?
| | Disease Progression | 3 | 2016 | 870 | 0.250 |
Why?
| | Single-Blind Method | 4 | 2008 | 130 | 0.250 |
Why?
| | Analysis of Variance | 6 | 2011 | 358 | 0.250 |
Why?
| | Chondromalacia Patellae | 3 | 2009 | 4 | 0.250 |
Why?
| | Health Care Surveys | 2 | 2014 | 77 | 0.250 |
Why?
| | Rheumatic Diseases | 1 | 2005 | 61 | 0.240 |
Why?
| | Pectoralis Muscles | 2 | 2015 | 19 | 0.240 |
Why?
| | Pressure | 6 | 2015 | 69 | 0.240 |
Why?
| | Meta-Analysis as Topic | 7 | 2020 | 45 | 0.240 |
Why?
| | Casts, Surgical | 1 | 2003 | 8 | 0.240 |
Why?
| | Prevalence | 4 | 2015 | 554 | 0.230 |
Why?
| | Occlusive Dressings | 1 | 2003 | 2 | 0.230 |
Why?
| | Lacerations | 2 | 2013 | 16 | 0.230 |
Why?
| | Mesenchymal Stem Cell Transplantation | 2 | 2020 | 32 | 0.230 |
Why?
| | Risk Assessment | 6 | 2017 | 814 | 0.230 |
Why?
| | Osteolysis | 2 | 2016 | 154 | 0.230 |
Why?
| | Surgical Wound Infection | 2 | 2018 | 106 | 0.230 |
Why?
| | Regression Analysis | 4 | 2014 | 326 | 0.230 |
Why?
| | Patient Care | 1 | 2023 | 36 | 0.230 |
Why?
| | Health Surveys | 2 | 2021 | 102 | 0.230 |
Why?
| | Survival Rate | 3 | 2021 | 443 | 0.230 |
Why?
| | Aggrecans | 3 | 2019 | 196 | 0.220 |
Why?
| | Knee | 4 | 2020 | 47 | 0.220 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2022 | 30 | 0.220 |
Why?
| | Publishing | 1 | 2023 | 40 | 0.220 |
Why?
| | Synovial Membrane | 3 | 2013 | 83 | 0.220 |
Why?
| | Retinal Degeneration | 1 | 2021 | 5 | 0.220 |
Why?
| | Health Status Indicators | 3 | 2012 | 83 | 0.210 |
Why?
| | Creatine | 1 | 2021 | 5 | 0.210 |
Why?
| | Practice Guidelines as Topic | 2 | 2015 | 388 | 0.210 |
Why?
| | Placenta | 1 | 2021 | 16 | 0.210 |
Why?
| | Electromyography | 3 | 2016 | 92 | 0.210 |
Why?
| | Collagen | 4 | 2013 | 114 | 0.210 |
Why?
| | Pregnancy | 2 | 2021 | 466 | 0.200 |
Why?
| | Private Practice | 2 | 2014 | 6 | 0.200 |
Why?
| | Internship and Residency | 3 | 2021 | 209 | 0.200 |
Why?
| | Ambulatory Surgical Procedures | 3 | 2016 | 78 | 0.200 |
Why?
| | Amniotic Fluid | 1 | 2020 | 5 | 0.200 |
Why?
| | Radio Waves | 3 | 2008 | 8 | 0.200 |
Why?
| | Polymers | 4 | 2019 | 44 | 0.200 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2021 | 13 | 0.200 |
Why?
| | Dermis | 1 | 2020 | 7 | 0.200 |
Why?
| | Body Mass Index | 4 | 2020 | 478 | 0.200 |
Why?
| | Practice Management, Medical | 1 | 2020 | 3 | 0.190 |
Why?
| | Perioperative Period | 1 | 2020 | 13 | 0.190 |
Why?
| | Polycarboxylate Cement | 3 | 2010 | 8 | 0.190 |
Why?
| | Ketones | 3 | 2019 | 18 | 0.190 |
Why?
| | Benzophenones | 3 | 2019 | 27 | 0.190 |
Why?
| | Compressive Strength | 4 | 2008 | 37 | 0.190 |
Why?
| | Education, Medical, Graduate | 2 | 2019 | 93 | 0.190 |
Why?
| | Primary Cell Culture | 1 | 2020 | 25 | 0.190 |
Why?
| | Research | 1 | 2020 | 62 | 0.190 |
Why?
| | Diagnostic Imaging | 2 | 2015 | 101 | 0.190 |
Why?
| | Movement | 3 | 2018 | 164 | 0.190 |
Why?
| | Molar | 1 | 2019 | 1 | 0.190 |
Why?
| | Models, Biological | 3 | 2019 | 397 | 0.190 |
Why?
| | Mandibular Nerve | 1 | 2019 | 4 | 0.190 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 20 | 0.190 |
Why?
| | Cross-Sectional Studies | 6 | 2021 | 1058 | 0.190 |
Why?
| | Symptom Assessment | 1 | 2020 | 24 | 0.190 |
Why?
| | Bone Diseases | 2 | 2019 | 27 | 0.190 |
Why?
| | ROC Curve | 4 | 2020 | 155 | 0.190 |
Why?
| | Temperature | 2 | 2018 | 86 | 0.190 |
Why?
| | Polyethylene Glycols | 3 | 2019 | 56 | 0.180 |
Why?
| | Self Report | 3 | 2019 | 245 | 0.180 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 63 | 0.180 |
Why?
| | Ankle | 1 | 2019 | 19 | 0.180 |
Why?
| | Fracture Fixation, Internal | 1 | 2019 | 72 | 0.180 |
Why?
| | Consensus | 1 | 2019 | 121 | 0.180 |
Why?
| | Chronic Disease | 3 | 2012 | 554 | 0.180 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 182 | 0.180 |
Why?
| | Polyurethanes | 2 | 2010 | 10 | 0.180 |
Why?
| | Feasibility Studies | 1 | 2020 | 282 | 0.180 |
Why?
| | Aging | 4 | 2022 | 1634 | 0.170 |
Why?
| | Probability | 3 | 2007 | 105 | 0.170 |
Why?
| | Patients | 1 | 2019 | 35 | 0.170 |
Why?
| | Research Subjects | 1 | 2018 | 13 | 0.170 |
Why?
| | Statistics, Nonparametric | 2 | 2010 | 156 | 0.170 |
Why?
| | Fluoroscopy | 2 | 2011 | 55 | 0.170 |
Why?
| | Infant | 1 | 2021 | 661 | 0.170 |
Why?
| | Propionibacterium acnes | 1 | 2018 | 8 | 0.170 |
Why?
| | Thyroidectomy | 1 | 1998 | 24 | 0.170 |
Why?
| | Carcinoma, Papillary | 1 | 1998 | 24 | 0.170 |
Why?
| | Mental Health | 1 | 2020 | 132 | 0.170 |
Why?
| | Doxycycline | 1 | 2018 | 24 | 0.170 |
Why?
| | Odds Ratio | 4 | 2020 | 321 | 0.170 |
Why?
| | Blood Specimen Collection | 1 | 2018 | 13 | 0.170 |
Why?
| | Horses | 2 | 2016 | 29 | 0.170 |
Why?
| | Delivery of Health Care | 1 | 2020 | 166 | 0.170 |
Why?
| | Surgery Department, Hospital | 1 | 1998 | 9 | 0.160 |
Why?
| | Prospective Payment System | 1 | 1998 | 4 | 0.160 |
Why?
| | Diagnosis-Related Groups | 1 | 1998 | 10 | 0.160 |
Why?
| | Coronavirus Infections | 1 | 2020 | 96 | 0.160 |
Why?
| | Durapatite | 1 | 1997 | 11 | 0.160 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 101 | 0.160 |
Why?
| | Molecular Weight | 1 | 2017 | 57 | 0.160 |
Why?
| | Pandemics | 1 | 2020 | 253 | 0.160 |
Why?
| | Biomedical Research | 1 | 2019 | 95 | 0.160 |
Why?
| | Thyroid Neoplasms | 1 | 1998 | 50 | 0.160 |
Why?
| | Medical Staff, Hospital | 1 | 1998 | 21 | 0.160 |
Why?
| | Carboplatin | 1 | 1997 | 54 | 0.160 |
Why?
| | Medical Records | 1 | 1998 | 36 | 0.160 |
Why?
| | Histiocytoma, Benign Fibrous | 1 | 1997 | 6 | 0.160 |
Why?
| | Humeral Fractures | 1 | 2017 | 22 | 0.160 |
Why?
| | Paclitaxel | 1 | 1997 | 79 | 0.160 |
Why?
| | Pneumonia | 1 | 2018 | 75 | 0.160 |
Why?
| | Pyridones | 1 | 2017 | 18 | 0.160 |
Why?
| | Fever | 1 | 2017 | 40 | 0.160 |
Why?
| | Body Height | 3 | 2015 | 45 | 0.160 |
Why?
| | Extracellular Matrix Proteins | 2 | 2015 | 171 | 0.160 |
Why?
| | Education, Medical, Continuing | 2 | 2013 | 47 | 0.160 |
Why?
| | Bone Morphogenetic Protein 2 | 3 | 2012 | 47 | 0.160 |
Why?
| | Soft Tissue Neoplasms | 1 | 1997 | 28 | 0.160 |
Why?
| | Osteoporosis | 1 | 2018 | 79 | 0.160 |
Why?
| | Observer Variation | 3 | 2012 | 142 | 0.150 |
Why?
| | Gait | 2 | 2016 | 419 | 0.150 |
Why?
| | Achilles Tendon | 2 | 2014 | 23 | 0.150 |
Why?
| | Disclosure | 1 | 2016 | 19 | 0.150 |
Why?
| | Immunohistochemistry | 2 | 2008 | 471 | 0.150 |
Why?
| | Tensile Strength | 3 | 2019 | 32 | 0.150 |
Why?
| | Electronic Health Records | 1 | 2017 | 84 | 0.150 |
Why?
| | Head and Neck Neoplasms | 1 | 1997 | 141 | 0.140 |
Why?
| | Brain Concussion | 1 | 2016 | 16 | 0.140 |
Why?
| | Orthopedic Fixation Devices | 1 | 2016 | 24 | 0.140 |
Why?
| | Disability Evaluation | 3 | 2020 | 340 | 0.140 |
Why?
| | Deltoid Muscle | 1 | 2015 | 6 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1997 | 207 | 0.140 |
Why?
| | Patient Compliance | 1 | 2017 | 200 | 0.140 |
Why?
| | Capsaicin | 1 | 2015 | 12 | 0.140 |
Why?
| | Rats, Sprague-Dawley | 2 | 2007 | 484 | 0.140 |
Why?
| | Bone Marrow Transplantation | 2 | 2010 | 41 | 0.140 |
Why?
| | Arthrography | 2 | 2015 | 26 | 0.140 |
Why?
| | Prosthesis-Related Infections | 1 | 2018 | 217 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 378 | 0.130 |
Why?
| | Thoracic Nerves | 1 | 2015 | 3 | 0.130 |
Why?
| | Mononeuropathies | 1 | 2015 | 3 | 0.130 |
Why?
| | Paralysis | 1 | 2015 | 19 | 0.130 |
Why?
| | Bone-Patellar Tendon-Bone Grafts | 1 | 2014 | 4 | 0.130 |
Why?
| | Mice | 6 | 2021 | 1958 | 0.130 |
Why?
| | Epinephrine | 2 | 2006 | 32 | 0.130 |
Why?
| | Anti-Bacterial Agents | 1 | 2018 | 434 | 0.130 |
Why?
| | Surgical Procedures, Operative | 2 | 2009 | 41 | 0.130 |
Why?
| | Knee Dislocation | 2 | 2005 | 7 | 0.130 |
Why?
| | Musculoskeletal System | 1 | 2014 | 6 | 0.130 |
Why?
| | Palliative Care | 2 | 2007 | 158 | 0.130 |
Why?
| | Societies, Medical | 1 | 2016 | 214 | 0.130 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 29 | 0.130 |
Why?
| | Ilium | 1 | 2014 | 31 | 0.130 |
Why?
| | New England | 1 | 2014 | 4 | 0.130 |
Why?
| | Elementary Particles | 1 | 2014 | 5 | 0.130 |
Why?
| | Quantum Theory | 1 | 2014 | 6 | 0.130 |
Why?
| | Acupuncture | 1 | 2013 | 2 | 0.120 |
Why?
| | Guided Tissue Regeneration | 1 | 2013 | 11 | 0.120 |
Why?
| | Placebos | 1 | 2014 | 83 | 0.120 |
Why?
| | Elbow | 3 | 2021 | 40 | 0.120 |
Why?
| | Models, Educational | 1 | 2013 | 41 | 0.120 |
Why?
| | Computer-Assisted Instruction | 1 | 2013 | 29 | 0.120 |
Why?
| | Medical Records Systems, Computerized | 1 | 2013 | 12 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2014 | 78 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2014 | 107 | 0.120 |
Why?
| | Acromioclavicular Joint | 1 | 2013 | 18 | 0.120 |
Why?
| | Cross-Over Studies | 1 | 2013 | 86 | 0.120 |
Why?
| | Primary Health Care | 1 | 2014 | 107 | 0.120 |
Why?
| | Longitudinal Studies | 1 | 2017 | 1485 | 0.120 |
Why?
| | Cell Death | 5 | 2007 | 68 | 0.120 |
Why?
| | Hospitalization | 1 | 2016 | 367 | 0.120 |
Why?
| | Bone Marrow Cells | 2 | 2020 | 65 | 0.120 |
Why?
| | Stilbenes | 1 | 2012 | 7 | 0.110 |
Why?
| | Reference Values | 3 | 2010 | 250 | 0.110 |
Why?
| | Osteophyte | 2 | 2012 | 6 | 0.110 |
Why?
| | Polyphenols | 1 | 2012 | 9 | 0.110 |
Why?
| | Cell Proliferation | 4 | 2019 | 232 | 0.110 |
Why?
| | ADAM Proteins | 1 | 2013 | 92 | 0.110 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2012 | 6 | 0.110 |
Why?
| | Chondrosarcoma | 1 | 2012 | 38 | 0.110 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2012 | 23 | 0.110 |
Why?
| | Bone Morphogenetic Protein 7 | 2 | 2012 | 64 | 0.110 |
Why?
| | Microscopy, Confocal | 4 | 2007 | 128 | 0.110 |
Why?
| | Joint Prosthesis | 1 | 2013 | 85 | 0.110 |
Why?
| | Goats | 2 | 2009 | 10 | 0.110 |
Why?
| | Equipment Failure | 2 | 2017 | 56 | 0.110 |
Why?
| | Arm Injuries | 1 | 2012 | 11 | 0.110 |
Why?
| | Transforming Growth Factors | 1 | 2011 | 2 | 0.110 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2011 | 5 | 0.110 |
Why?
| | Fibroblast Growth Factors | 1 | 2011 | 9 | 0.110 |
Why?
| | Braces | 2 | 2016 | 26 | 0.110 |
Why?
| | Ceramics | 1 | 2011 | 23 | 0.110 |
Why?
| | Osseointegration | 1 | 2012 | 76 | 0.100 |
Why?
| | Synovitis | 1 | 2011 | 22 | 0.100 |
Why?
| | Acute Disease | 2 | 2010 | 258 | 0.100 |
Why?
| | Age Distribution | 3 | 2016 | 109 | 0.100 |
Why?
| | Joint Capsule Release | 1 | 2011 | 6 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2012 | 118 | 0.100 |
Why?
| | Epiphyses | 2 | 2020 | 13 | 0.100 |
Why?
| | Work Capacity Evaluation | 1 | 2010 | 8 | 0.100 |
Why?
| | Hot Temperature | 2 | 2008 | 26 | 0.100 |
Why?
| | Resistance Training | 1 | 2010 | 8 | 0.100 |
Why?
| | Dissection | 1 | 2010 | 29 | 0.100 |
Why?
| | Software | 2 | 2021 | 77 | 0.100 |
Why?
| | Ultrasonography, Interventional | 1 | 2011 | 75 | 0.090 |
Why?
| | Documentation | 2 | 2022 | 34 | 0.090 |
Why?
| | Comorbidity | 2 | 2018 | 563 | 0.090 |
Why?
| | Transplants | 1 | 2009 | 11 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 3 | 2015 | 42 | 0.090 |
Why?
| | Hypertrophy | 1 | 2009 | 25 | 0.090 |
Why?
| | Prosthesis Fitting | 1 | 2009 | 23 | 0.090 |
Why?
| | Fallopian Tube Diseases | 1 | 2009 | 1 | 0.090 |
Why?
| | Organ Size | 1 | 2009 | 119 | 0.090 |
Why?
| | Infertility, Female | 1 | 2009 | 23 | 0.090 |
Why?
| | Asepsis | 1 | 2008 | 3 | 0.090 |
Why?
| | Anesthetics | 1 | 2009 | 27 | 0.090 |
Why?
| | Risk | 2 | 2020 | 228 | 0.090 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2008 | 16 | 0.090 |
Why?
| | Substance P | 1 | 2008 | 19 | 0.090 |
Why?
| | Dogs | 2 | 2008 | 275 | 0.090 |
Why?
| | Body Weight | 1 | 2009 | 167 | 0.090 |
Why?
| | Models, Statistical | 1 | 2009 | 145 | 0.090 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 1997 | 889 | 0.090 |
Why?
| | Torque | 3 | 2017 | 26 | 0.080 |
Why?
| | Axons | 1 | 2008 | 44 | 0.080 |
Why?
| | Elasticity | 1 | 2008 | 49 | 0.080 |
Why?
| | Transplantation | 1 | 2008 | 5 | 0.080 |
Why?
| | Histocytochemistry | 1 | 2008 | 34 | 0.080 |
Why?
| | Horse Diseases | 1 | 2008 | 7 | 0.080 |
Why?
| | Logistic Models | 2 | 2020 | 474 | 0.080 |
Why?
| | Egypt | 1 | 2007 | 3 | 0.080 |
Why?
| | Management Information Systems | 1 | 2007 | 3 | 0.080 |
Why?
| | Smoking | 3 | 2018 | 206 | 0.080 |
Why?
| | Hip Joint | 1 | 2011 | 370 | 0.080 |
Why?
| | Internal Fixators | 1 | 2007 | 55 | 0.080 |
Why?
| | Quality-Adjusted Life Years | 3 | 2014 | 24 | 0.080 |
Why?
| | Tissue Preservation | 1 | 2006 | 6 | 0.070 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2006 | 6 | 0.070 |
Why?
| | Arachidonic Acid | 1 | 2006 | 16 | 0.070 |
Why?
| | Ultrasonic Therapy | 1 | 2006 | 22 | 0.070 |
Why?
| | Collagen Type II | 2 | 2019 | 33 | 0.070 |
Why?
| | Drug Combinations | 1 | 2006 | 89 | 0.070 |
Why?
| | Mechanics | 1 | 2006 | 4 | 0.070 |
Why?
| | Forecasting | 2 | 2005 | 136 | 0.070 |
Why?
| | Arthroscopes | 2 | 2007 | 9 | 0.070 |
Why?
| | Muscle Weakness | 1 | 2006 | 37 | 0.070 |
Why?
| | Tissue and Organ Procurement | 1 | 2006 | 37 | 0.070 |
Why?
| | Hyperthermia, Induced | 2 | 2005 | 5 | 0.070 |
Why?
| | Jogging | 1 | 2005 | 3 | 0.070 |
Why?
| | Medial Collateral Ligament, Knee | 1 | 2006 | 7 | 0.070 |
Why?
| | Muscular Atrophy | 1 | 2005 | 9 | 0.070 |
Why?
| | Fractures, Compression | 1 | 2005 | 7 | 0.070 |
Why?
| | Glucosamine | 1 | 2005 | 14 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2006 | 139 | 0.070 |
Why?
| | Sulfur Radioisotopes | 1 | 2005 | 19 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2019 | 181 | 0.070 |
Why?
| | Sulfates | 1 | 2005 | 21 | 0.070 |
Why?
| | Joints | 1 | 2006 | 101 | 0.070 |
Why?
| | Chondroitin Sulfates | 1 | 2005 | 40 | 0.070 |
Why?
| | Education, Continuing | 1 | 2005 | 17 | 0.070 |
Why?
| | Fractures, Spontaneous | 1 | 2005 | 11 | 0.070 |
Why?
| | Equipment Safety | 1 | 2005 | 14 | 0.070 |
Why?
| | Bone Marrow Diseases | 1 | 2005 | 9 | 0.070 |
Why?
| | Osteonecrosis | 1 | 2005 | 19 | 0.070 |
Why?
| | Shoulder Fractures | 1 | 2005 | 24 | 0.070 |
Why?
| | Sex Distribution | 2 | 2016 | 92 | 0.070 |
Why?
| | Arthrometry, Articular | 2 | 2017 | 14 | 0.070 |
Why?
| | Fracture Fixation | 1 | 2005 | 24 | 0.070 |
Why?
| | Edema | 1 | 2005 | 39 | 0.070 |
Why?
| | Joint Capsule | 1 | 2005 | 45 | 0.070 |
Why?
| | Image Enhancement | 1 | 2005 | 61 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 148 | 0.060 |
Why?
| | Diet | 1 | 2006 | 228 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 249 | 0.060 |
Why?
| | Decision Support Techniques | 2 | 2014 | 57 | 0.060 |
Why?
| | Glycosaminoglycans | 2 | 2017 | 69 | 0.060 |
Why?
| | Prosthesis Design | 2 | 2019 | 534 | 0.060 |
Why?
| | Surface Properties | 2 | 2009 | 152 | 0.060 |
Why?
| | Ligaments | 1 | 2023 | 17 | 0.060 |
Why?
| | Radiostereometric Analysis | 1 | 2023 | 7 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 494 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 229 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 563 | 0.060 |
Why?
| | Medical Illustration | 2 | 2015 | 20 | 0.060 |
Why?
| | Pulmonary Edema | 1 | 2003 | 17 | 0.060 |
Why?
| | Vasoconstrictor Agents | 1 | 2003 | 30 | 0.060 |
Why?
| | Skin Temperature | 1 | 2003 | 2 | 0.060 |
Why?
| | Recombinant Proteins | 3 | 1999 | 289 | 0.060 |
Why?
| | Fascia Lata | 1 | 2023 | 7 | 0.060 |
Why?
| | Interleukin-1beta | 2 | 2013 | 59 | 0.060 |
Why?
| | Confidence Intervals | 3 | 2009 | 102 | 0.060 |
Why?
| | Obesity | 1 | 2006 | 359 | 0.060 |
Why?
| | Intraoperative Complications | 1 | 2003 | 73 | 0.060 |
Why?
| | Gene Expression | 2 | 2013 | 267 | 0.060 |
Why?
| | Indazoles | 1 | 2022 | 3 | 0.050 |
Why?
| | Microscopy, Electron, Scanning | 2 | 2002 | 91 | 0.050 |
Why?
| | Automation | 1 | 2021 | 12 | 0.050 |
Why?
| | Pyridines | 1 | 2022 | 47 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 42 | 0.050 |
Why?
| | Inositol | 1 | 2021 | 8 | 0.050 |
Why?
| | Rats, Inbred Lew | 2 | 1999 | 13 | 0.050 |
Why?
| | Metabolomics | 1 | 2021 | 24 | 0.050 |
Why?
| | Fetus | 1 | 2001 | 66 | 0.050 |
Why?
| | Imidazoles | 1 | 2022 | 73 | 0.050 |
Why?
| | Lipids | 1 | 2021 | 57 | 0.050 |
Why?
| | Chorion | 1 | 2020 | 2 | 0.050 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2020 | 3 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2021 | 40 | 0.050 |
Why?
| | Umbilical Cord | 1 | 2020 | 5 | 0.050 |
Why?
| | Computers | 1 | 2021 | 28 | 0.050 |
Why?
| | Glucose | 1 | 2021 | 78 | 0.050 |
Why?
| | Chromatography, Liquid | 1 | 2020 | 26 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2020 | 28 | 0.050 |
Why?
| | Expert Testimony | 1 | 2020 | 17 | 0.050 |
Why?
| | Registries | 2 | 2019 | 226 | 0.050 |
Why?
| | Osteogenesis | 2 | 1999 | 99 | 0.050 |
Why?
| | Area Under Curve | 1 | 2020 | 77 | 0.050 |
Why?
| | Steroids | 1 | 2020 | 31 | 0.050 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2014 | 234 | 0.050 |
Why?
| | Personal Satisfaction | 1 | 2020 | 57 | 0.050 |
Why?
| | Survival Analysis | 2 | 1998 | 372 | 0.050 |
Why?
| | Sports | 1 | 2020 | 39 | 0.050 |
Why?
| | Ultrasonography | 1 | 2001 | 215 | 0.050 |
Why?
| | Commerce | 1 | 2020 | 13 | 0.050 |
Why?
| | Proteomics | 1 | 2020 | 90 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2019 | 15 | 0.050 |
Why?
| | Delphi Technique | 1 | 2019 | 28 | 0.050 |
Why?
| | Thrombin | 1 | 2019 | 14 | 0.050 |
Why?
| | Fibrinogen | 1 | 2019 | 32 | 0.050 |
Why?
| | Inflammation | 2 | 2012 | 396 | 0.050 |
Why?
| | Rehabilitation | 1 | 2019 | 15 | 0.050 |
Why?
| | Quality Assurance, Health Care | 1 | 2020 | 56 | 0.050 |
Why?
| | Morphine | 1 | 2020 | 79 | 0.050 |
Why?
| | Health Care Costs | 1 | 2020 | 83 | 0.050 |
Why?
| | Motion Therapy, Continuous Passive | 1 | 2019 | 5 | 0.040 |
Why?
| | Desiccation | 1 | 2019 | 6 | 0.040 |
Why?
| | Platelet Count | 1 | 2019 | 23 | 0.040 |
Why?
| | Immobilization | 1 | 1999 | 12 | 0.040 |
Why?
| | Medicare | 1 | 2020 | 129 | 0.040 |
Why?
| | Ischemia | 1 | 1999 | 35 | 0.040 |
Why?
| | Angiography | 1 | 1999 | 58 | 0.040 |
Why?
| | Bone Density | 1 | 2019 | 144 | 0.040 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 1998 | 2 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2019 | 80 | 0.040 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 83 | 0.040 |
Why?
| | Nitric Oxide | 2 | 2009 | 105 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 1998 | 36 | 0.040 |
Why?
| | Carcinoma, Lobular | 1 | 1998 | 16 | 0.040 |
Why?
| | Tissue Banks | 1 | 2018 | 8 | 0.040 |
Why?
| | Forms and Records Control | 1 | 1998 | 10 | 0.040 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 1998 | 36 | 0.040 |
Why?
| | Interferon-beta | 1 | 1997 | 8 | 0.040 |
Why?
| | Operating Rooms | 1 | 2018 | 20 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 1997 | 27 | 0.040 |
Why?
| | Patient Admission | 1 | 1998 | 30 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2019 | 99 | 0.040 |
Why?
| | Michigan | 1 | 2017 | 20 | 0.040 |
Why?
| | Porosity | 1 | 1997 | 74 | 0.040 |
Why?
| | Femoral Neck Fractures | 1 | 1997 | 13 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1997 | 76 | 0.040 |
Why?
| | Prosthesis Implantation | 1 | 1997 | 40 | 0.040 |
Why?
| | Skin | 1 | 2018 | 136 | 0.040 |
Why?
| | Fibrosis | 1 | 2017 | 57 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 1997 | 177 | 0.040 |
Why?
| | Tarsal Bones | 1 | 2016 | 7 | 0.040 |
Why?
| | Muscle Fatigue | 1 | 2017 | 10 | 0.040 |
Why?
| | Computer-Aided Design | 1 | 2017 | 16 | 0.040 |
Why?
| | Torso | 1 | 2017 | 8 | 0.040 |
Why?
| | Interleukins | 1 | 2017 | 43 | 0.040 |
Why?
| | Industry | 1 | 2016 | 10 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 1997 | 98 | 0.040 |
Why?
| | Titanium | 1 | 1997 | 219 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 1997 | 449 | 0.040 |
Why?
| | Online Systems | 1 | 2016 | 7 | 0.040 |
Why?
| | Early Ambulation | 1 | 2016 | 20 | 0.040 |
Why?
| | Current Procedural Terminology | 1 | 2016 | 14 | 0.040 |
Why?
| | Anemia, Sickle Cell | 1 | 1996 | 13 | 0.040 |
Why?
| | Proprioception | 1 | 2016 | 21 | 0.040 |
Why?
| | History, 21st Century | 1 | 2016 | 38 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2016 | 23 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2015 | 3 | 0.040 |
Why?
| | History, 20th Century | 1 | 2016 | 89 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2016 | 73 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2015 | 22 | 0.040 |
Why?
| | Photography | 1 | 2015 | 18 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 49 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 1996 | 68 | 0.030 |
Why?
| | Hypertension | 1 | 2018 | 293 | 0.030 |
Why?
| | Kidney Glomerulus | 1 | 1996 | 96 | 0.030 |
Why?
| | Program Evaluation | 1 | 2016 | 150 | 0.030 |
Why?
| | Perioperative Care | 1 | 2016 | 74 | 0.030 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 28 | 0.030 |
Why?
| | Rupture, Spontaneous | 1 | 2014 | 7 | 0.030 |
Why?
| | False Negative Reactions | 1 | 2014 | 14 | 0.030 |
Why?
| | Video Recording | 1 | 2015 | 52 | 0.030 |
Why?
| | Occupational Injuries | 1 | 2015 | 9 | 0.030 |
Why?
| | Immunization | 1 | 1994 | 50 | 0.030 |
Why?
| | Thorax | 1 | 2014 | 15 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 38 | 0.030 |
Why?
| | Family | 1 | 1996 | 114 | 0.030 |
Why?
| | Medical History Taking | 1 | 2014 | 26 | 0.030 |
Why?
| | Posture | 1 | 2015 | 90 | 0.030 |
Why?
| | Denmark | 1 | 2014 | 13 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 61 | 0.030 |
Why?
| | Hemostatic Techniques | 1 | 2014 | 10 | 0.030 |
Why?
| | Thigh | 1 | 2014 | 35 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2014 | 26 | 0.030 |
Why?
| | Mesons | 1 | 2014 | 5 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2016 | 151 | 0.030 |
Why?
| | Electrons | 1 | 2014 | 23 | 0.030 |
Why?
| | Kidney Diseases | 1 | 1996 | 152 | 0.030 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 2013 | 7 | 0.030 |
Why?
| | Anti-Infective Agents | 1 | 2014 | 63 | 0.030 |
Why?
| | Kidney Transplantation | 1 | 1996 | 153 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 38 | 0.030 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2013 | 35 | 0.030 |
Why?
| | Learning Curve | 1 | 2013 | 21 | 0.030 |
Why?
| | Muscle Strength Dynamometer | 1 | 2013 | 16 | 0.030 |
Why?
| | Acellular Dermis | 1 | 2013 | 7 | 0.030 |
Why?
| | Hip | 1 | 2013 | 41 | 0.030 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2013 | 3 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2013 | 14 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 178 | 0.030 |
Why?
| | Integrins | 1 | 2013 | 29 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 1998 | 435 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2013 | 8 | 0.030 |
Why?
| | Analgesics | 1 | 2014 | 113 | 0.030 |
Why?
| | Metals | 1 | 2014 | 171 | 0.030 |
Why?
| | Clavicle | 1 | 2013 | 15 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2013 | 117 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2013 | 123 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2013 | 30 | 0.030 |
Why?
| | Linear Models | 1 | 2013 | 275 | 0.030 |
Why?
| | Metabolism | 1 | 2012 | 12 | 0.030 |
Why?
| | Oncogene Protein v-akt | 1 | 2012 | 14 | 0.030 |
Why?
| | Plants | 1 | 2012 | 10 | 0.030 |
Why?
| | Peptide Hydrolases | 1 | 2012 | 19 | 0.030 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2012 | 24 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 33 | 0.030 |
Why?
| | Species Specificity | 1 | 2012 | 76 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2012 | 30 | 0.030 |
Why?
| | Artificial Cells | 1 | 2012 | 1 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 71 | 0.030 |
Why?
| | Proteins | 1 | 2012 | 95 | 0.030 |
Why?
| | Secondary Prevention | 1 | 2012 | 69 | 0.030 |
Why?
| | Gamma Rays | 1 | 2012 | 17 | 0.030 |
Why?
| | Erythrocytes | 1 | 2012 | 24 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2013 | 399 | 0.030 |
Why?
| | Blood Platelets | 1 | 2012 | 51 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 287 | 0.030 |
Why?
| | Transcription Factors | 1 | 2012 | 176 | 0.030 |
Why?
| | Device Removal | 1 | 2012 | 100 | 0.030 |
Why?
| | Coronary Disease | 1 | 1991 | 101 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 2002 | 244 | 0.030 |
Why?
| | Apoptosis | 1 | 2012 | 288 | 0.030 |
Why?
| | Behavior Therapy | 1 | 1991 | 90 | 0.020 |
Why?
| | Occupations | 1 | 2010 | 16 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 278 | 0.020 |
Why?
| | Neutrophils | 1 | 2011 | 139 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 350 | 0.020 |
Why?
| | Functional Laterality | 1 | 2010 | 94 | 0.020 |
Why?
| | Signal Transduction | 1 | 2012 | 590 | 0.020 |
Why?
| | Fertility Agents, Female | 1 | 2009 | 1 | 0.020 |
Why?
| | Hysterosalpingography | 1 | 2009 | 2 | 0.020 |
Why?
| | Nigeria | 1 | 2009 | 4 | 0.020 |
Why?
| | Clomiphene | 1 | 2009 | 5 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 2009 | 22 | 0.020 |
Why?
| | Hip Prosthesis | 1 | 1995 | 622 | 0.020 |
Why?
| | Sheep | 1 | 2008 | 40 | 0.020 |
Why?
| | Preservation, Biological | 1 | 2008 | 5 | 0.020 |
Why?
| | Cold Temperature | 1 | 2008 | 37 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 2009 | 59 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2008 | 46 | 0.020 |
Why?
| | Biopsy | 1 | 2008 | 277 | 0.020 |
Why?
| | Fractures, Bone | 1 | 2007 | 72 | 0.020 |
Why?
| | Mice, SCID | 1 | 2006 | 64 | 0.020 |
Why?
| | Cell Movement | 1 | 2006 | 119 | 0.020 |
Why?
| | Minicomputers | 1 | 2005 | 1 | 0.020 |
Why?
| | Selection Bias | 1 | 2005 | 10 | 0.020 |
Why?
| | Thermography | 1 | 2005 | 13 | 0.020 |
Why?
| | Body Temperature | 1 | 2005 | 73 | 0.020 |
Why?
| | Immunoassay | 1 | 1984 | 47 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2001 | 86 | 0.010 |
Why?
| | Polyglycolic Acid | 1 | 1999 | 2 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 1999 | 2 | 0.010 |
Why?
| | Drug Carriers | 1 | 1999 | 9 | 0.010 |
Why?
| | Lactic Acid | 1 | 1999 | 20 | 0.010 |
Why?
| | Rhode Island | 1 | 1998 | 3 | 0.010 |
Why?
| | Massachusetts | 1 | 1998 | 24 | 0.010 |
Why?
| | Axilla | 1 | 1998 | 15 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1998 | 92 | 0.010 |
Why?
| | Lymphatic Metastasis | 1 | 1998 | 101 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 1998 | 387 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 1998 | 457 | 0.010 |
Why?
| | Histocompatibility | 1 | 1996 | 5 | 0.010 |
Why?
| | HLA Antigens | 1 | 1996 | 20 | 0.010 |
Why?
| | Haplotypes | 1 | 1996 | 62 | 0.010 |
Why?
| | Glomerulonephritis | 1 | 1996 | 27 | 0.010 |
Why?
| | Equipment Reuse | 1 | 1995 | 4 | 0.010 |
Why?
| | Hospitals, Special | 1 | 1995 | 7 | 0.010 |
Why?
| | Cost Control | 1 | 1995 | 11 | 0.010 |
Why?
| | New York City | 1 | 1995 | 23 | 0.010 |
Why?
| | Stress, Physiological | 1 | 1994 | 26 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1994 | 34 | 0.010 |
Why?
| | Program Development | 1 | 1995 | 75 | 0.010 |
Why?
| | Lymphocytes | 1 | 1994 | 116 | 0.010 |
Why?
| | Hypercholesterolemia | 1 | 1991 | 39 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 1984 | 20 | 0.000 |
Why?
| | Laboratories | 1 | 1984 | 27 | 0.000 |
Why?
| | Quality Control | 1 | 1984 | 52 | 0.000 |
Why?
| | Thyroxine | 1 | 1984 | 96 | 0.000 |
Why?
| | Triiodothyronine | 1 | 1984 | 113 | 0.000 |
Why?
|
|
Cole's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|